Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement Read more
Sanyou Biopharmaceuticals and KangaBio established strategic collaboration to accelerate antibody drug development and innovation Read more
Bota Bio and Medichem Announce Commercial Development Collaboration to Advance Sustainable Pharmaceutical Manufacturing Read more
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off Read more
ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene Therapy Innovation Read more
FDA Approves IMBRUVICA (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease Read more
First Gene Therapy for Adults with Severe Hemophilia A, BioMarin’s ROCTAVIAN (valoctocogene roxaparvovec), Approved by EC Read more
Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy R&D and Manufacturing Center Read more